Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium/formoterol versus monotherapies and tiotropium in stable COPD
2015-005444-33Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aclidinium, formoterol and tiotropium in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by AstraZeneca. Started Apr 2016; status: completed.
02
Drugs
aclidiniumformoteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-005444-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005444-33.